Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Cook G, Ashcroft AJ, Senior E, Olivier C, Hockaday A, Richards J, Cavenagh JD, Snowden JA, Drayson MT, de Tute R, Roberts L, Owen RG, Yong K, Garg M, Boyd K, Sati H, Gillson S, Cook M, Cairns DA, Parrish C; United Kingdom Myeloma Research Alliance.
Cook G, et al. Among authors: boyd k.
Lancet Haematol. 2024 Nov;11(11):e816-e829. doi: 10.1016/S2352-3026(24)00249-7. Epub 2024 Sep 6.
Lancet Haematol. 2024.
PMID: 39250926
Free article.
Clinical Trial.